Retrophin Inc. Cmn (RTRX) 18.49 $RTRX Anavex's Lead

New Post Public Reply Private Reply Replies (0) Message Board

Jun 24, 2016 at 1:05 AM

Retrophin Inc. Cmn (RTRX) 18.49 $RTRX

Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:22PM CDT
Anavex Life Sciences (AVXL) announced that ANAVEX 2-73 has been granted orphan drug status by the FDA for the treatment of infantile spasms.
AVXL: 4.27 (+0.12), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), ACOR: 26.31 (+1.04)

Nymox (NYMX) Stock Up on Positive 7-Year Fexapotide Data
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:51AM CDT
Nymox (NYMX) announced positive results from the seven-year, prospective, placebo-controlled, double-blind study on fexapotide (NX-1207).
ANIP: 56.27 (+3.48), PFE: 34.59 (+0.12), RTRX: 18.49 (+0.01), NYMX: 2.91 (-0.24)

Retrophin Announces New Data from Physician-Initiated Treatment with RE-024 at the 20th International Congress of Parkinson's Disease and Movement Disorders
GlobeNewswire - Thu Jun 23, 5:00AM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced new data from physician-initiated treatment with RE-024, the company's novel investigational replacement therapy for pantothenate kinase-associated neurodegeneration (PKAN), a rare and life-threatening genetic condition characterized by a host of progressively debilitating movement disorders. Key findings suggest RE-024 was safe and well tolerated in two adults with PKAN who experienced clinically meaningful improvements, followed by stabilization of disease progression over 47 weeks of treatment.
RTRX: 18.49 (+0.01)

Prima Reports Favorable Initial Breast Cancer Study Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 2:30PM CDT
Prima BioMed Ltd (PBMD) announced initial data from a phase IIb chemo-immunotherapy study on IMP321 for the treatment of metastatic breast cancer.
PBMD: 1.03 (+0.01), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), CELG: 100.66 (+1.43)

GW Pharma (GWPH) to Develop Epidiolex for Infantile Spasms
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:53AM CDT
GW Pharmaceuticals (GWPH) has selected infantile spasms as the fourth target indication for the development of Epidiolex.
GWPH: 89.14 (+0.57), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), BMY: 72.64 (+0.33)

Inovio Stock Up, Zika Vaccine Gets Nod for Phase I Study
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 3:51PM CDT
Inovio Pharmaceuticals (INO) and GeneOne Life Science will begin the first Zika vaccine study in human volunteers; Inovio's stock gains.
INO: 9.85 (-0.35), ANIP: 56.27 (+3.48), XON: 25.20 (+0.55), RTRX: 18.49 (+0.01)

Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:46AM CDT
Fate Therapeutics (FATE) announced that the FDA has granted the Fast Track status to its immunotherapy ProTmune.
FATE: 1.83 (unch), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), ACOR: 26.31 (+1.04)

Gilead Presents Favorable Preliminary Bictegravir HIV Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:21AM CDT
Gilead Sciences (GILD) presented encouraging preliminary data from four pre-clinical and phase I studies evaluating bictegravir for the treatment of HIV.
GILD: 83.37 (+0.92), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), BMY: 72.64 (+0.33)

Auris (EARS) Begins Phase III Study for Sudden Deafness
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 9:31AM CDT
Auris Medical (EARS) has started patient enrollment in a second pivotal phase III study (ASSENT) on AM-111 for the treatment of sudden deafness.
EARS: 4.00 (-0.05), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), BMY: 72.64 (+0.33)

Kura (KURA) Begins Dosing in Phase II Study on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 3:18PM CDT
Kura Oncology (KURA) announced the dosing of the first patient in a phase II study on tipifarnib for the treatment of lower risk myelodysplastic syndromes.
JNJ: 117.38 (+0.92), RTRX: 18.49 (+0.01), KURA: 2.69 (+0.04), BMY: 72.64 (+0.33)

7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.46 (+0.01), RTRX: 18.49 (+0.01), AVEO: 0.98 (-0.01), SNSS: 0.55 (-0.01), LGND: 115.11 (+1.28), BIND: 0.40 (-0.01), ACOR: 26.31 (+1.04)

Zacks.com featured highlights: Dycom Industries, QVC Group, Retrophin, Facebook and Gener8 Maritime
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:30AM CDT
Zacks.com featured highlights: Dycom Industries, QVC Group, Retrophin, Facebook and Gener8 Maritime
GNRT: 6.89 (+0.25), FB: 115.08 (+1.17), RTRX: 18.49 (+0.01), QVCA: 24.90 (+0.15), DY: 89.88 (+2.07)

5 Profitable Stocks for Enhancing Your Portfolio Returns
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:18AM CDT
Among the profitability ratios, we have used net income ratio to determine a company's profitability position.
GNRT: 6.89 (+0.25), FB: 115.08 (+1.17), RTRX: 18.49 (+0.01), QVCA: 24.90 (+0.15), DY: 89.88 (+2.07)

Revance's Lead Candidate Fails in Phase III Crow's Feet Study
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 10:28AM CDT
Revance Therapeutics' (RVNC) RT001 topical failed to meet the co-primary and other endpoints in a phase III crow's feet study.
PFE: 34.59 (+0.12), RTRX: 18.49 (+0.01), RVNC: 13.99 (+0.34), BMY: 72.64 (+0.33)

Agios Reports Favorable Phase II PK Deficiency Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:56AM CDT
Agios Pharmaceuticals (AGIO) reported encouraging initial data from an ongoing phase II DRIVE-PK study on pyruvate kinase deficiency candidate AG-348.
PFE: 34.59 (+0.12), RTRX: 18.49 (+0.01), AGIO: 48.50 (+1.43), BMY: 72.64 (+0.33)

Glaxo/J&J Sirukumab Positive in Rheumatoid Arthritis Study
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:01AM CDT
GlaxoSmithKline (GSK) and Johnson & Johnson's Janssen Biologics announced encouraging new phase III study data on rheumatoid arthritis candidate, sirukumab.
JNJ: 117.38 (+0.92), RTRX: 18.49 (+0.01), GSK: 42.56 (+0.80), BMY: 72.64 (+0.33)

The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 6.12 (-0.08), BIIB: 238.62 (+4.02), IDRA: 1.53 (+0.05), RTRX: 18.49 (+0.01), ACOR: 26.31 (+1.04)

Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 0.50 (+0.04), RTRX: 18.49 (+0.01), VVUS: 1.10 (unch), ARNA: 1.91 (+0.06)

Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 6.12 (-0.08), BIIB: 238.62 (+4.02), IDRA: 1.53 (+0.05), RTRX: 18.49 (+0.01), LGND: 115.11 (+1.28), ACOR: 26.31 (+1.04)

Teva's Pain Drug Vantrela Recommended for FDA Approval
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 8:50AM CDT
Teva Pharmaceutical's (TEVA) Vantrela has been recommended for approval in the U.S.
PFE: 34.59 (+0.12), RTRX: 18.49 (+0.01), TEVA: 51.37 (+0.18), BMY: 72.64 (+0.33)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mastering Progressive Overload: Break Workout Plateaus

Getting off the Fitness Merry-Go-Round You've been hitting the gym, feeling great, and suddenly—bam! You've hit a wall so hard you might as well be a bug on a windshield. That's where our buddy Joshua Bankes comes in, explaining the magic of progressive overload for fitness buffs. Understanding Plateau Phenomena Remember, results aren't linear. As you start a new...

Decoding Real Estate Value: A Market Insider's Take

Riding the Waves of Real Estate Pricing Homeowners dipping their toes into the real estate market know that setting the right price ain't a walk in the park. Luckily, Matt Nuzie, Shelton's real estate pro, has peeled back the layers on comparative market analyses (CMA) in a HelloNation piece. This isn't just about tossing a number out there—it's about understanding the...

Aiper’s Black Friday Pool Deals Make a Splash

Black Friday: A Pool Owner's Break It’s not every day you stumble upon savings like these—Aiper is throwing some meaty discounts this Black Friday, saving pool owners up to a juicy $550 off robotic cleaners. Imagine that! For anyone with a pool to maintain, these deals might just be the ticket to less grunt work and more time lounging with a cold drink in hand....

Isinwheel's 2027 E-Mobility Pitch: Beyond Resolutions

Embracing the E-Mobility Shift Here we are at the tail end of 2026, and isinwheel is riding high on the wave of New Year resolutions with their hefty e-mobility lineup. It's not just about buying the gear—it's about tackling our reliance on gas-guzzlers with electric scooters and bikes as our trusty steeds. "Reduce car trips? More greenery in your commute? These aren't...

TESSAN and Jamie Leibert's Daring Alpine Documentary Launch

Steps Beyond the Obvious Adventure Launching headlong into the unknown—literally and figuratively—is what the documentary Jump Into The Unknown captures. TESSAN and Jamie Leibert have peeled back the curtain on adventure, showing us that it’s not just about the destination, but every twist, turn, and recalibrated step in between. The Backstory Behind Every Jump...

Home Genius Exteriors Expands with Five New Locations

Pushing Beyond the Backyard: Home Genius Opens New Doors Hold onto your hats, folks. Home Genius Exteriors is making a splashy move by setting up shop in five new points across the map. We're talking Toledo, Ohio; Nashville, Tennessee; Lehigh Valley and Erie in Pennsylvania; and Dover, Delaware. That's quite a leap from their cozy base of operations, marking a clear push...

Orthocell's Remplir™ Hits Record U.S. Sales in October

Orthocell's October Surprise with Remplir™ Sales Well, isn't this a breath of fresh air? Orthocell Limited just reported a staggering rise in its U.S. Remplir™ sales for October 2026. We're talking 92 units shifting off the shelves, pulling in a tidy AU$279,000. That's an 84% leap compared to the average monthly sales of 50 units in Q1 FY27. It seems the company's...

Can AI Help Climate? Tech Investments Seek Balance

Is AI a Climate Savior or a Power-Hungry Beast? AI might feel like that unpredictable family member you hope shows up to the party with something useful, but they’ve always got high energy bills. As the tech world touts artificial intelligence as the next big hope for addressing climate woes, folks like Peter Gilmer—who's been around a few boardrooms—are taking a...

Roof Flashing Insights with Expert Jeremiah Lightsey

Why Flashing Is the Backbone of a Leak-Free Roof Ever wonder why some roofs just seem to withstand the wrath of Mother Nature better? The answer, my friends, often boils down to a little unsung hero: roof flashing. Our roof parts aren't exactly playing an even game; you've got chimneys, walls, skylights, just asking for trouble. That's where flashing steps in like an...

Strategic Leap: Context Labs Sets Roots in Abu Dhabi

Breaking New Ground in AI Infrastructure Well, folks, we're witnessing an intriguing strategic move here that could potentially reshape the AI landscape across the MENA region. Context Labs, the masterminds behind the AI Data Infrastructure, have roped in a powerful ally in the form of 22/x, a frontrunner in the Abu Dhabi investment scene. And no, this isn't just about...